Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has agreed to acquire Antula with brands such as SB12, Anti, Zyx, Becur, Ac3, Lactal Balans, Eeze, Nalox and Inside, for SEK1800m, as part of its plan to build a strong position in OTC products, an area that it has continually expanded in recent years.
Subscribe to our email newsletter
Antula is established in the Nordics with its own organization.
The acquisition of Antula offers Meda clear growth opportunities, partly through Meda and Antula’s existing prescription-free (OTC) products, and partly through Antula’s pipeline that consists of three to four new products annually.
Through the integration with Meda, several of the products are expected to have potential to become international brands.
Antula’s and Meda’s OTC products will together make up over 20% of Meda’s total sales.
The transaction is subject to standard closing requirements and the approval of the competition authorities. The acquisition of Antula is expected to be completed within a couple of months.